Drug Type Small molecule drug |
Synonyms APT 102 (Apie Therapeutics), APT102 (Apie Therapeutics) |
Target |
Mechanism CD39 agonists(Ectonucleoside triphosphate diphosphohydrolase 1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Apie Therapeutics, Inc.Startup |
Active Organization Apie Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metabolic Syndrome | Preclinical | US | Apie Therapeutics, Inc.Startup | 22 Nov 2023 |
Nephrotic Syndrome | Preclinical | US | Apie Therapeutics, Inc.Startup | 22 Nov 2023 |